Literature DB >> 19751843

Blockade of neutrophil responses in aspiration pneumonia via ELR-CXC chemokine antagonism does not predispose to airway bacterial outgrowth.

Xixing Zhao1, Jennifer R Town, Fang Li, Wei Li, Xiaobei Zhang, John R Gordon.   

Abstract

Pneumonia associated with aspiration of bacterial-laden gastric contents is characterized by Glu-Leu-Arg (ELR)-CXC chemokine (e.g., CXC2L1, CXCL8) expression leading to local neutrophil sequestration. This neutrophil response is designed to be protective, but overly aggressive responses can be pathogenic in themselves. Herein we assessed whether blocking neutrophil responses in a guinea pig model of aspiration pneumonia would foster airway bacterial growth. Guinea pigs (n=5) were challenged intranasally with saline, acidified saline or acidified gastric contents (35mg/kg body weight, pH 2.0) and treated subcutaneously with 250mug/kg of the human ELR-CXC chemokine antagonist CXCL8((3-72))K11R/G31P (G31P) or saline. After 20h the animals' airway inflammatory responses and bacterial burdens were assessed. A loss of vascular integrity was apparent in the lungs of the saline-treated aspiration pneumonia animals (12.07+/-1.3% of the pleural surfaces exhibited hemorrhagic consolidation, 4.6x10(6) RBC/ml bronchoalveolar lavage fluid [BALF]), as was a pulmonary neutrophilia. The BAL fluids contained gram-negative and -positive bacteria (total load, 6.3+/-3.2x10(7) CFU/ml BALF) that are associated with nosocomial infections in humans. The G31P-treatments attenuated the pulmonary vascular complications (2.27+/-0.5% pleural surface hemorrhagic consolidation, 0.46x10(6) RBC/ml BALF), and reduced the pulmonary neutrophilia by >/=86%. The G31P-treatments did not lead to significant changes in the airway bacterial loads (total load, 3.46+/-1.8x10(7) CFU/ml BALF). This data indicates that attenuation of the pulmonary neutrophil response in aspiration pneumonia reduces pathology very significantly but does not reduce the efficiency of pulmonary bacterial clearance. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19751843     DOI: 10.1016/j.pupt.2009.09.001

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  7 in total

1.  In vivo imaging of transiently transgenized mice with a bovine interleukin 8 (CXCL8) promoter/luciferase reporter construct.

Authors:  Fabio Franco Stellari; Valentina Franceschi; Antonio Capocefalo; Marcello Ronchei; Fabrizio Facchinetti; Gino Villetti; Gaetano Donofrio
Journal:  PLoS One       Date:  2012-06-28       Impact factor: 3.240

Review 2.  CXCR2 in acute lung injury.

Authors:  F M Konrad; J Reutershan
Journal:  Mediators Inflamm       Date:  2012-06-06       Impact factor: 4.711

3.  CXCR1/2 antagonism with CXCL8/Interleukin-8 analogue CXCL8(3-72)K11R/G31P restricts lung cancer growth by inhibiting tumor cell proliferation and suppressing angiogenesis.

Authors:  Muhammad Noman Khan; Bing Wang; Jing Wei; Yingqiu Zhang; Qiang Li; Xuelin Luan; Jya-Wei Cheng; John R Gordon; Fang Li; Han Liu
Journal:  Oncotarget       Date:  2015-08-28

Review 4.  Future Directions and Molecular Basis of Ventilator Associated Pneumonia.

Authors:  Kubra Aykac; Yasemin Ozsurekci; Sevgen Tanir Basaranoglu
Journal:  Can Respir J       Date:  2017-10-15       Impact factor: 2.409

5.  Effects of K11R and G31P Mutations on the Structure and Biological Activities of CXCL8: Solution Structure of Human CXCL8(3-72)K11R/G31P.

Authors:  Hsi-Tsung Cheng; Hui-Yuan Yu; John R Gordon; Fang Li; Jya-Wei Cheng
Journal:  Molecules       Date:  2017-07-21       Impact factor: 4.411

6.  Porcine CXCR1/2 antagonist CXCL8(3-72)G31P inhibits lung inflammation in LPS-challenged mice.

Authors:  Xue Wang; Yanchuan Li; Lintao Li; Zhe Jiao; Xiaoli Liu; Guofu Cheng; Changqin Gu; Xueying Hu; Wanpo Zhang
Journal:  Sci Rep       Date:  2020-01-27       Impact factor: 4.379

7.  CXCR1/CXCR2 antagonism is effective in pulmonary defense against Klebsiella pneumoniae infection.

Authors:  Jing Wei; Jing Peng; Bing Wang; Hong Qu; Shiyi Wang; Aziz Faisal; Jia-Wei Cheng; John R Gordon; Fang Li
Journal:  Biomed Res Int       Date:  2013-03-18       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.